Key result
Pediatric Crohn's disease is linked to a ~67% lower plasma phospholipid n-6/n-3 PUFA ratio.
Why the study?
Are plasma fatty acid profiles altered in newly diagnosed treatment-naïve pediatric Crohn's disease compared to healthy controls?
Observational (n=42)
No
Are plasma fatty acid profiles altered in newly diagnosed treatment-naïve pediatric Crohn's disease compared to healthy controls?
The metabolism of polyunsaturated fatty acids is significantly altered in treatment-naïve pediatric Crohn's disease, with major fatty acid contents correlating with disease activity and inflammatory markers.
Answers are grounded in this paper and cite their sources.
Altered plasma PUFA profiles in untreated pediatric CD should not yet change practice; leaves open their contribution to early pathogenesis.
Fatty acid (FA) profiles as potentially relevant components of Crohn’s disease (CD) have been insufficiently analysed. We sought to explore the plasma profiles of n-3 and n-6 polyunsa-turated fatty acids (PUFAs) in newly diagnosed untreated active CD. We included 26 consecutive CD pediatric patients (<19 years) and 14 healthy controls (HCs). Disease characteristics, including inflammatory markers, dietary histories, and the Pediatric Crohn’s Disease Activity Index (PCDAI), were obtained. The profiles of plasma FAs in plasma lipid classes were analysed by gas chromatography with FID detection of methyl esters. The erythrocyte sedimentation rate, C-reactive protein level and fecal calprotectin level (all p<0.001) were significantly higher in CD patients than in HCs. Most changes were observed in plasma phospholipids (PLs), such as a higher content of n-3 and changes in n-6 long-chain PUFAs in the CD group. The CD group had a lower ratio of n-6/n-3 PUFAs in PLs (p<0.001) and triacylglycerols (TAGs) (p<0.01). Correlations of the FA content in plasma PLs with disease activity scores of CD were also observed, which were positive for the sum of monounsaturated fatty acids (MUFAs) as well as oleic acid (18:1n-9) (both p<0.05). The metabolism of PUFAs is significantly altered even in treatment-naïve newly diagnosed active pediatric CD, and the content of major FAs in PLs correlates with disease activity and inflammatory markers, thus probably contributing to the still unclear early disease pathogenesis.
No takes yet. Share an insight, caveat, or question.
Schwarz et al. (2021) conducted an observational in Pediatric Crohn's disease (n=42). Newly diagnosed Crohn's disease vs. Healthy controls was evaluated on Ratio of n-6/n-3 PUFAs in plasma phospholipids (p=<0.001). Newly diagnosed, treatment-naïve pediatric Crohn's disease patients exhibited significantly altered polyunsaturated fatty acid metabolism, including a lower ratio of n-6/n-3 PUFAs in plasma phospholipids compared to healthy controls.
Synapse has enriched 10 related papers. Consider them for comparative context: